Evolution of coronary stents in patients with diabetes: are clinical outcomes still improving?

References

• Jensen LO, Maeng M, Thayssen P, et al. Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol 2010;105:1513-19
   Google Scholar
• Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population based autopsy study. J Am Coll Cardiol 2002;40:946-53
   PubMed Web of Science ®Google Scholar
• Silva JA, Escobar A, Collins TJ, et al. Unstable angina: a comparison of angioscopic findings between diabetic and non-diabetic patients. Circulation 1995;92:1731-6
   PubMed Web of Science ®Google Scholar
• Vavuranakis M, Stefanadis C, Toutouzas K, et al. Impaired compensatory coronary artery enlargement in atherosclerosis contributes to the development of coronary artery stenosis in diabetic patients: an in vivo intravascular ultrasound study. Eur Heart J 1997;18:1090-4
   Google Scholar
• Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9
   PubMed Web of Science ®Google Scholar
• Qin SY, Zhou Y, Jiang HX, et al. The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One 2013;8:e72710
   Google Scholar
• West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004;109:867-73
   PubMed Web of Science ®Google Scholar
• Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8
   PubMed Web of Science ®Google Scholar
• Sabate M, Jimenez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83
   PubMed Web of Science ®Google Scholar
• Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, et al. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. EuroIntervention 2013;9:328-35
   Google Scholar
• Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9
   PubMed Web of Science ®Google Scholar
• Patti G, Nusca A, Di Sciascio G. Meta-analysis comparison (nine trials) of outcomes with drug-eluting stents versus bare metal stents in patients with diabetes mellitus. Am J Cardiol 2008;102:1328-34
   Google Scholar
• Lagerqvist B, Carlsson J, Frobert O, et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv 2009;2:401-8
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-41
   PubMed Web of Science ®Google Scholar
• Stenestrand U, James SK, Lindback J, et al. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010;31:177-86
   PubMed Web of Science ®Google Scholar
• Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-9
   PubMed Web of Science ®Google Scholar
• Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, et al. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet 2009;373:911-18
   PubMed Web of Science ®Google Scholar
• Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation 2009;119:687-98
   Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008;52:1134-40
   PubMed Web of Science ®Google Scholar
• Jensen LO, Maeng M, Thayssen P, et al. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. Eur Heart J 2008;29:2733-41
   Google Scholar
• Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70
   PubMed Web of Science ®Google Scholar
• Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008;52:727-33
   PubMedGoogle Scholar
• Maeng M, Jensen LO, Galloe AM, et al. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009;103:345-9
   PubMed Web of Science ®Google Scholar
• Kuchulakanti PK, Chu WW, Torguson R, et al. Sirolimus-eluting stents versus paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 2006;98:187-92
   Google Scholar
• Stankovic G, Cosgrave J, Chieffo A, et al. Impact of sirolimus-eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 2006;98:362-6
   Google Scholar
• Tarantini G, Facchin M, Capodanno D, et al. Paclitaxel versus sirolimus eluting stents in diabetic patients: does stent type and/or stent diameter matter?: long-term clinical outcome of 2,429-patient multicenter registry. Catheter Cardiovasc Interv 2013;81:80-9
   PubMed Web of Science ®Google Scholar
• Jensen LO, Maeng M, Thayssen P, et al. Late lumen loss and intima hyperplasia after sirolimus-eluting and zotarolimus-eluting stent implantation in diabetic patients: the diabetes and drug-eluting stent (DiabeDES III) angiography and intravascular ultrasound trial. EuroIntervention 2011;7:323-31
   Google Scholar
• Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011;124:893-900
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Comparison of an everolimus eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903-13
   PubMed Web of Science ®Google Scholar
• Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT V Diabetic Study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J 2012;163:867-75
   PubMed Web of Science ®Google Scholar
• Kim WJ, Lee SW, Park SW, et al. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial. Circulation 2011;124:886-92
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Cutlip DE, Applegate RJ, et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxeleluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010;56:2084-9
   PubMed Web of Science ®Google Scholar
• Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9
   PubMed Web of Science ®Google Scholar
• Kedhi E, Gomes ME, Lagerqvist B, et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. JACC Cardiovasc Interv 2012;5:1141-9
   PubMed Web of Science ®Google Scholar
• Laynez A, Sardi G, Hauville C, et al. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population. Catheter Cardiovasc Interv 2013;81:759-65
   Google Scholar
• Jensen LO, Thayssen P, Junker A, et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol 2012;110:1585-91
   PubMed Web of Science ®Google Scholar
• Kimura T, Morimoto T, Natsuaki M, et al. Comparison of Everolimus-eluting and Sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET). Circulation 2012;126:1225-36
   PubMed Web of Science ®Google Scholar
• Simsek C, Räber L, Magro M, et al. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study. Int J Cardiol 2013;170:36-42
   PubMed Web of Science ®Google Scholar
• Park GM, Lee SW, Park SW, et al. Comparison of zotarolimus-eluting stent versussirolimus-eluting stent for de novo coronary artery disease in patients with diabetes mellitus from the Essence-Diabetes II Trial. Am J Cardiol 2013;112:1565-70
   Google Scholar
• Jang SJ, Park DW, Kim WJ, et al. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and non-diabetic patients: two-year subgroup analysis of the ZEST randomized trial. Catheter Cardiovasc Interv 2013;81:1106-14
   Google Scholar
• Maeng M, Jensen LO, Tilsted HH, et al. Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy). Am J Cardiol 2011;108:1232-7
   Google Scholar
• deWaha A, Stefanini GG, King LA, et al. Long-term outcomes of biodegradable polymer versus durable polymer drug-eluting stents in patients with diabetes a pooled analysis of individual patient data from 3 randomized trials. Int J Cardiol 2013;168:5162-6
   Google Scholar
• Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012;345:e5170
   PubMedGoogle Scholar
• Bernelli C, Chan J, Chieffo A. Drug-eluting stent outcomes in diabetes. Expert Rev Cardiovasc Ther 2014;12:95-109
   Google Scholar